We found that TRIM22 show varied expression across different cancer types, with significantly higher expression in GBM, head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), metastatic skin cutaneous melanoma (SKCM), and thyroid carcinoma (THCA) (Fig. 1A). Here, TRIM22 is linked to thyroid gland carcinoma.